Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01870726
Title Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma
Recruitment Terminated
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals



Buparlisib + Capmatinib

Age Groups: adult
Covered Countries USA | ESP | DEU

Facility Status City State Zip Country Details
Dana Farber Cancer Institute SC Boston Massachusetts 02215 United States Details
Columbia University Medical Center- New York Presbyterian Dept of Oncology New York New York 10032 United States Details
Memorial Sloan Kettering Cancer Center Neurology New York New York 90033 United States Details
Duke University Medical Center Duke - Baker Durham North Carolina 27710 United States Details
University of Texas MD Anderson Cancer Center SC-3 Houston Texas 77030 United States Details
Novartis Investigative Site Bonn 53105 Germany Details
Novartis Investigative Site Heidelberg 69120 Germany Details
Novartis Investigative Site Tübingen 72076 Germany Details
ErasmusMC Cancer Institute - Neurooncology, RM G3-55 Rotterdam 3075EA Netherlands Details
University Medical Center Utrecht, Rm Q05.4.300, P.O. Box 85500 Utrecht 3508 GA Netherlands Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Madrid 28041 Spain Details
Novartis Investigative Site St. Gallen 9007 Switzerland Details
*Shaded cells indicate that there was no data available from for the field